Inactivated Influenza Vaccines: (trivalent and quadrivalent) IIV3, IIV4, IIV3 ID, IIV3 High Dose

Annual influenza vaccination is recommended for all persons 6 months of age and older, including all healthy persons. Indications for Use and Schedule

-IIV3 (IM) or IIV4 (IM): For persons aged 6 months and older -Age range for use varies by brand

-IIV3 Intradermal (ID): For persons aged 18 through 64 years -IIV3 High Dose (IM): For persons aged 65 years and older Begin vaccinating as soon as flu vaccine is available and continue throughout the flu season (until vaccine expires)

2-Dose Pediatric Rule for Children aged 6 Months through 8 Years

-Because the vaccines strains are the same, children aged 6 months through 8 years who received at least 1 dose of 2013-14 seasonal flu vaccine from July1, 2013 through June 30, 2014 only need 1 dose of 2014-15 seasonal flu vaccine.

- However, some children in this age group may require 2 doses of flu vaccine to best protect them (separated by at least 4 weeks).

- Remember when assessing a child's flu vaccine history to determine if one or two doses are needed, only review flu vaccine doses given prior to July 1, 2014 (do not include doses received during the 2014-15 flu season. Refer to the CDC Pediatric 2-Dose Algorithm for Children 6 months through 8 years at

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm#Fig1

Administration

-Administer IIV3, IIV4 & IIV3 High Dose IM -Children: 1 inch needle -Adolescent/adults: 1-1.5 inch needle -Administer IIV3 ID only over deltoid area of arm, using the manufacturer's pre-filled syringe -Administer age-appropriate IIV3 or IIV4 dosage: 6-35 months → 0.25mL (each dose) 3 years & older \rightarrow 0.5mL (each dose) -IIV can be given with all other vaccines Storage and Handling -Store in the refrigerator unit at 35°-46°F (2°-8°C) -Do NOT freeze All -Keep in original box with lid on ΠV

-Store different IIV formulations Apart & label with age indication

-Do NOT use expired vaccine



Contraindications (Persons who should not receive IIV3/IIV4)

- · Serious allergic reaction (e.g. anaphylaxis) to a previous dose of flu vaccine or one of its components
- Precautions (In certain circumstances may receive IIV3/IIV4)
- Moderate to severe acute illness
- History of Guillain-Barre´ Syndrome (GBS) within 6 weeks of a previous influenza vaccination

**NOTE: Persons who report an egg allergy: give Recombinant Influenza Vaccine, trivalent (RIV3) to those aged 18-49 years if available or, determine if it is safe to give Inactivated Influenza Vaccine, trivalent (IIV3) or quadrivalent (IIV4). -Refer to the CDC Vaccine Screening Algorithm for Persons who report an Egg Allergy at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm#Fig2

Further Points to consider

- IIV3 (including IIV3 ID & IIV3 High Dose): contains protection again 2 "A" flu strains and 1 "B" flu strain
- IIV4: Contains protection against 2 "A" flu strains (same as IIV3) and 2 "B" flu strains (1 same as IIV3 & 1 additional "B" strain)
- Febrile seizures occur in 2-5% of all children. Following simultaneous administration of IIV & PCV13, an increased risk for febrile seizures (<1 per 1,000 children vaccinated) was observed in children aged 16 mos-4 yrs. ACIP considered benefit of receiving IIV & PCV13 versus risk; no changes in recommendation have been made and, if needed, IIV & PCV13 should be given simultaneously.
- Use current IIV VIS for any brand/type of IIV3 or IIV4.
- · Give only IIV formulations with antiviral medications; Do not give LAIV: For further information: www.cdc.gov/flu
- Document the type of vaccine given on the vaccine administration record & record card as "IIV3", IIV4" "IIV3 ID" or IIV3 High Dose"
- ACIP has not expressed a preference between any IIV3 (including IIV3 ID, IIV3 High Dose) and IIV4 formulation
- There are 2 other IIV3 formulations not included on this form; refer to package inserts for information on Recombinant Inactivated Vaccine, trivalent (RIV3; Flublok, Protein Science) or cell-cultured Inactivated Influenza Vaccine, trivalent (ccIIV3; Flucelvax, Novartis)

¹ For further guidance on the influenza recommendations and the preference for LAIV4, refer to the "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP, U.S., 2014-15 Influenza Season," MMWR, Vol.63(32); 691-697 8/15/14 located at http://www.cdc/gov/vaccines